Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

Author：                      

Publisher： Spandidos Publications

ISSN： 1021-335X

Source： Oncology Reports, Vol.28, Iss.2, 2012-01, pp. : 654-658

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MGMT promoter methylation in plasma of glioma patients receiving temozolomide

By Fiano Valentina   Trevisan Morena   Trevisan Elisa   Senetta Rebecca   Castiglione Anna   Sacerdote Carlotta   Gillio-Tos Anna   Marco Laura   Grasso Chiara   Magistrello Michela   Tondat Fabrizio   Rudà Roberta   Cassoni Paola   Soffietti Riccardo   Merletti Franco  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 347-357

Springer Publishing Company

Access to resources Recommend Favorite

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By Rocha Lima Caio M.   Bayraktar Soley   Flores Aurea M.   MacIntyre Jessica   Montero Alberto   Baranda Joaquina C.   Wallmark John   Portera Chia   Raja Rajiv   Stern Howard   Royer-Joo Stephanie   Amler Lukas C.  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 727-731

Informa Healthcare

Access to resources Recommend Favorite

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

By Kochi Mitsugu   Akiyama Yuji   Aoki Tatsuya   Hagiwara Ken   Takahashi Takao   Hironaka Katsuji   Teranishi Futoshi   Osuka Fumihiko   Takeuchi Masahiro   Fujii Masashi   Nakajima Toshifusa  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1097-1102

Springer Publishing Company

Access to resources Recommend Favorite

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation

By Capdevila Laia   Cros Sara   Ramirez Jose-Luis   Sanz Carolina   Carrato Cristina   Romeo Margarita   Etxaniz Olatz   Hostalot Cristina   Massuet Ana   Cuadra Jose   Villà Salvador   Balañà Carmen  

Journal of Neuro-Oncology, Vol. 117, Iss. 1, 2014-03 ,pp. : 77-84

Springer Publishing Company

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite